Medtronic (MDT +0.63%) has finally settled with Edwards Lifesciences (EW +2.45%) regarding allegations of infringing on Edwards' patents by marketing and selling the CoreValve transcatheters. The settlement worked out to a $750 million one-time payment and royalty payments on CoreValve sales from now until 2022.
Obviously, Edwards shareholders have got to be pleased that management's strong defense of its patents has paid off so handsomely, and the additional revenues from that victory are welcome news for any company.
Medtronic's shareholders also may have good reason to be pleased, as there will be no more lawsuits from now until 2022 -- and the company had suffered a series of legal setbacks in this patent dispute.
In this video, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts David Williamson and Michael Douglass discuss the settlement's winners and losers.
